COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cabazitaxel in Relapsed and Metastatic NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01852578
Recruitment Status : Completed
First Posted : May 13, 2013
Last Update Posted : September 28, 2015
Information provided by (Responsible Party):
Hellenic Oncology Research Group

Brief Summary:
The investigators propose to study the single agent activity of Cabazitaxel in a Phase II trial of subjects with relapsed or refractory non-small cell lung cancer pretreated with docetaxel, given the fact of its significant activity and its acceptable toxicity profile.

Condition or disease Intervention/treatment Phase
NSCLC Drug: Cabazitaxel Phase 2

Detailed Description:

Non small cell lung cancer represents the second most common type of cancer in both men and women in the Western world. The availability of new active regimens in the first line setting has prompted several investigators to consider second line therapy for patients with advanced NSCLC, since a substantial percentage of patients maintain a good PS upon recurrence. On the basis of the results of phase III trials docetaxel, erlotinib, gefitinib, or pemetrexed are considered as "standard" choices for second-line therapy.

However, despite the increased availability of different drugs, NSCLC remains a devastating disease with median OS which rarely exceeds 12 months.

Preclinical data of cabazitaxel have demonstrated antitumor activity in models resistant to paclitaxel and docetaxel. In cell lines resistant to cytotoxic agents, cabazitaxel induced further tumor regression.

The recommended phase 2 doses for Cabazitaxle were 20 and 25 mg/m2. Cabazitaxel showed antitumor activity in solid tumors including docetaxel-refractory metastatic castration-resistant prostate cancer and breast cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Phase II Trial of Cabazitaxel in Patients With Metastatic NSCLC Progressing After Docetaxel-based Treatment
Study Start Date : September 2012
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Cabazitaxel

Arm Intervention/treatment
Experimental: 1 Drug: Cabazitaxel
Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
Other Name: Jevtana

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Disease evaluation at Week 6 ]

Secondary Outcome Measures :
  1. Disease control rate [ Time Frame: Disease evaluation at Week 6 ]
    Disease control rate is defined as the proportion of patients with complete response plus partial response plus stable disease

  2. Progression Free Survival [ Time Frame: 1 year ]
  3. Overall Survival [ Time Frame: 1 year ]
  4. Toxicity profile [ Time Frame: Every 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age>18 years old
  • Cytologically or histologically documented NSCLC
  • PS 0-2 (WHO scale)
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (at least one measurable lesion)
  • Documented disease progression to previous treatment with docetaxel regimen in 1st or 2nd line setting assessed by Response Evaluation Criteria in Solid Tumors with at least one visceral or soft-tissue metastatic lesion.
  • Brain metastases are allowed, given that are clinically stable and the patient does not present neurologic symptoms.
  • Previous radiotherapy, either in the adjuvant setting or for the treatment of bone metastases, is allowed provided that the measurable lesions are outside the radiation fields. Patients who were irradiated to ≥ 40% of bone marrow are not eligible for the study.
  • Patients must have a recent (within 7 days prior to treatment start) biochemical and hematogical assessment as defined by adequate bone marrow (absolute neutrophil count ≥1.5 x 109 cells/L, platelets ≥100 x 109cells/L and hemoglobin ≥9 g/dL), liver (AST & ALT ≤ 2.5x ULN, total bilirubin within normal range) and renal (serum creatinine < 1.5 x ULN). If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded) function tests
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
  • Before patient enrollment, written informed consent must be given according to ICH/GCP and national/local regulations.

Exclusion Criteria:

  • Persistence of clinically relevant treatment-related toxicities from previous chemotherapy or radiotherapy.
  • Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of treatment or concomitantly with this trial.
  • Other malignancy within the past five years other than basal cell skin cancer or carcinoma in situ of the cervix.
  • Patient with reproductive potential not implementing accepted and effective method of contraception
  • History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs or to docetaxel
  • Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus, hypertension, heart failure ≤ NYHA II, history of myocardial infarction within the past 6 months, angina, chronic obstructive pulmonary disease (COPD), serious infections requiring systemic antibiotic therapy (e.g. antimicrobial, antifungal, antiviral)
  • Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B)
  • Prior surgery, radiation, chemotherapy, within 4 weeks prior to treatment
  • Active grade ≥2 peripheral neuropathy
  • Active grade ≥2 stomatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01852578

Layout table for location information
"Ag. Georgios" General Hospital of Chania
Chania, Crete, Greece
University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece
Heraklion, Crete, Greece
"IASO" General Hospital of Athens Athens, Greece
Athens, Greece
Air Forces Military Hospital of Athens Athens, Greece
Athens, Greece
"PAPAGEORGIOY" General Hospital of Thessaloniki
Thessaloniki, Greece
Sponsors and Collaborators
Hellenic Oncology Research Group
Layout table for investigator information
Principal Investigator: Athanasio Kotsakis, MD University Hospital of Herklion
Layout table for additonal information
Responsible Party: Hellenic Oncology Research Group Identifier: NCT01852578    
Other Study ID Numbers: CT/12.02
First Posted: May 13, 2013    Key Record Dates
Last Update Posted: September 28, 2015
Last Verified: September 2015
Keywords provided by Hellenic Oncology Research Group:
Metastatic NSCLC
2nd Line
Docetaxel-based treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases